Annals of internal medicine
-
The authors posit the need for rapid evaluation of therapies for COVID-19 as an inflection point spurring a much-needed rethinking of our research enterprise.
-
The clinical utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies remains undefined. ⋯ Clinical Immunology Laboratory, Department of Pathology, Johns Hopkins Hospital.
-
Comment
Treatment effect of aspirin for primary prevention does not differ according to baseline ASCVD risk.
Nudy M, Cooper J, Ghahramani M, et al. Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: a meta-regression analysis. Am J Med. 2020;133:1056-64. 32445718.
-
The HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:1927-36. 32563378.